Literature DB >> 15306598

Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.

M Pascu1, P Martus, M Höhne, B Wiedenmann, U Hopf, E Schreier, T Berg.   

Abstract

BACKGROUND AND AIMS: There is growing evidence that the response of hepatitis C virus (HCV) genotype 1b infected patients towards interferon (IFN) therapy is influenced by the number of mutations within the carboxy terminal region of the NS5A gene, the interferon sensitivity determining region (ISDR). PATIENTS AND METHODS: In order to attain better insight into this correlation, a file comprising published data on ISDR strains from 1230 HCV genotype 1b infected patients, mainly from Japan and Europe, was constructed and analysed by logistic regression. Sustained virological response (SVR) was defined as negative HCV RNA six months after treatment.
RESULTS: The distribution of wild-, intermediate-, and mutant-type ISDR sequences differed significantly between Japanese (n = 655) (44.1%, 37.6%, and 18.3%) and European patients (n = 525) (24.8%, 63.4%, and 11.8%; p<0.001). There was a significant positive correlation between the number of ISDR mutations and SVR rate, irrespective of geographical region. The likelihood of SVR with each additional mutation within the ISDR was considerably more pronounced in Japanese compared with European patients (odds ratios 1.82 v 1.39; p<0.001). Pretreatment viraemia of <6.6 log copies/ml and ISDR mutant-type infection was associated with an SVR rate of 97.1% in Japanese patients but only 52.5% in European patients. Pretreatment viraemia was a stronger predictor of SVR than ISDR mutation number in Japanese patients whereas in European patients both parameters had similar predictive power.
CONCLUSION: These data support the concept that mutant-type ISDR strains may represent a subtype within genotype 1b with a more favourable response towards IFN therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306598      PMCID: PMC1774214          DOI: 10.1136/gut.2003.031336

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  45 in total

1.  Variations within hepatitis C virus E2 protein and response to interferon treatment.

Authors:  S Lo; H H Lin
Journal:  Virus Res       Date:  2001-06       Impact factor: 3.303

2.  Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.

Authors:  J Nousbaum; S J Polyak; S C Ray; D G Sullivan; A M Larson; R L Carithers; D R Gretch
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication.

Authors:  S J Polyak; D M Paschal; S McArdle; M J Gale; D Moradpour; D R Gretch
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

4.  Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response.

Authors:  G W Witherell; P Beineke
Journal:  J Med Virol       Date:  2001-01       Impact factor: 2.327

5.  Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection.

Authors:  H Watanabe; N Enomoto; K Nagayama; N Izumi; F Marumo; C Sato; M Watanabe
Journal:  J Infect Dis       Date:  2001-03-14       Impact factor: 5.226

6.  Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon.

Authors:  M Gerotto; F Dal Pero; P Pontisso; F Noventa; A Gatta; A Alberti
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

7.  Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.

Authors:  T Berg; A Mas Marques; M Höhne; B Wiedenmann; U Hopf; E Schreier
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

8.  Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy.

Authors:  P Halfon; G Halimi; M Bourlière; D Ouzan; J Durant; H Khiri; L Mercier; V Gerolami; G Cartouzou
Journal:  Liver       Date:  2000-10

9.  Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response.

Authors:  M Paterson; C D Laxton; H C Thomas; A M Ackrill; G R Foster
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

10.  The NS5a gene of hepatitis C virus in patients treated with interferon-alpha.

Authors:  V M McKechnie; P R Mills; E A McCruden
Journal:  J Med Virol       Date:  2000-04       Impact factor: 2.327

View more
  46 in total

1.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 2.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load.

Authors:  Koji Ishii; Mie Shinohara; Michio Kogame; Misato Shiratori; Katsuya Higami; Kaori Kanayama; Kazue Shiozawa; Noritaka Wakui; Hidenari Nagai; Manabu Watanabe; Yasukiyo Sumino
Journal:  Hepatol Int       Date:  2011-08-06       Impact factor: 6.047

Review 4.  Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance.

Authors:  James Lara; Yury Khudyakov
Journal:  Antivir Ther       Date:  2012-12-07

Review 5.  Sequence diversity of hepatitis C virus: implications for immune control and therapy.

Authors:  Joerg Timm; Michael Roggendorf
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

6.  Evolution of interferon-based therapy for chronic hepatitis C.

Authors:  Chun-Hao Chen; Ming-Lung Yu
Journal:  Hepat Res Treat       Date:  2010-10-10

7.  Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors.

Authors:  Verónica Saludes; Maria Alma Bracho; Oliver Valero; Mercè Ardèvol; Ramón Planas; Fernando González-Candelas; Vicente Ausina; Elisa Martró
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China.

Authors:  Jin-Song Peng; Xu Wang; Man-Qing Liu; Dun-Jin Zhou; Jie Gong; Han-Ming Xu; Jian-Ping Chen; Hong-Hao Zhu; Wang Zhou; Wen-Zhe Ho
Journal:  Virus Res       Date:  2008-03-18       Impact factor: 3.303

Review 9.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

10.  Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response.

Authors:  Cíntia Bittar; Ana Carolina G Jardim; Lilian H T Yamasaki; Artur T L de Queiróz; Claudia M A Carareto; João Renato R Pinho; Isabel Maria V G de Carvalho-Mello; Paula Rahal
Journal:  BMC Infect Dis       Date:  2010-02-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.